PROTECT

PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) is a collaborative European project funded through the European Commission. It addresses limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance.

Goal

The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. In order to achieve this overall goal, PROTECT has been designed to develop and validate a set of innovative tools and methods that will:

• Enhance data collection directly from consumers
• Improve early and proactive signal detection from spontaneous reports, electronic health records and clinical trials;
• Develop, test and disseminate methods for the design, conduct and analysis of pharmacoepidemiological studies
• Develop methods for benefit-risk assessment of medicines
• Test and validate various methods developed in PROTECT using a large variety of data sources

Partners

• Aarhus University
• Agencia Española de Medicamentos y Productos Sanitarios
• Amgen
• AstraZeneca
• Bayer
• Eli Lilly
• European Medicines Agency
• Roche
• Fundació Institut Català de Farmacologia
• Fundación Centro Español de Investigación Farmacoepidemiológica
• Genzyme
• GlaxoSmithKline
• General Practice Research Database
• Lundbeck
• Imperial College London
• Institut National de la Santé et de la Recherche Médicale
• International Alliance of Patients’ Organizations
• L.A. Santé Épidémiologie Evaluation Recherche
- Lægemiddelstyrelsen
- Ludwig-Maximilians-Universität München
- Mario Negri Institute for Pharmacological Research
- Medicines and Healthcare products Regulatory Agency
- Merck
- Novartis
- Novo Nordisk
- Outcome Europe Sarl
- Pfizer
- Poznan University of Medical Sciences
- Rijksuniversiteit Groningen
- Sanofi-Aventis
- Takeda
- Stiftelsen WHO Collaborating Centre for International Drug Monitoring
- University of Newcastle upon Tyne
- Universiteit Utrecht
- Witten/Herdecke University